Possibilities of reducing the cardiotoxicity of neoadjuvant polychemotherapy in a dose-intensive regimen in patients with locally advanced cervical cancer

Azhimamatova ZHyldyz Tynybekovna, ZHumabaev Amangeldi Rahmadildeevich, Belekov ZHanek Omoshevich

In 207patients with locally advanced cervical cancer (MRRM), the mean age is 46.6 years, the efficacy and cardiotoxicity of 3 cycles of neoadjuvant polychemotherapy (NPHT) cisplatin (75mg / m2) and paclitaxel (175mg / m2) in dose-intensive were studied also studied. The possibility of reducing cardiotoxicity in the process of NPHTs using the multicomponent drug Mexidol 200 ml 2 times a day with an interval of 12 hours with 200 ml of 6% dextrose before the start of NPHT for 4 days has also been studied. As a result of conducting NPHT in the dose-intensive mode, patients with MRRM allow radical surgical treatment in locally advanced cervical cancer in 96.4% of cases. Preliminary use of the drug Mexidol significantly reduces the cardiotoxic action of NPHT in the dose-intensive mode.

Keywords:locally advanced cervical cancer, dose-intensive neoadjuvant polychemotherapy, reduction of cardiotoxicity with Mexidol.